Lenvatinib as a Therapeutic Option in Unresectable Metastatic Pheochromocytoma and Paragangliomas.

Lauren Hassan NelsonHarry Fuentes-BayneJun YinErik AsmusMabel RyderJohn C MorrisCrystal R HilgerKeith C BibleAshish V ChintakuntlawarSarika N Rao

Published in: Journal of the Endocrine Society (2022)

Lenvatinib may be a viable treatment option for mPPGL, although at the potential risk of worsening hypertension. Larger, multicenter studies are needed to better characterize treatment efficacy.

Keyphrases

blood pressure
small cell lung cancer
squamous cell carcinoma
clinical trial
radiation therapy
risk assessment
climate change
smoking cessation